Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2010

01-12-2010 | Original Article

Association between cystatin C and inflammation in patients with essential hypertension

Authors: Takafumi Okura, Masanori Jotoku, Jun Irita, Daijiro Enomoto, Tomoaki Nagao, Veena Rasika Desilva, Shiho Yamane, Zuowei Pei, Shiho Kojima, Yasuyuki Hamano, Shinichi Mashiba, Mie Kurata, Ken-ichi Miyoshi, Jitsuo Higaki

Published in: Clinical and Experimental Nephrology | Issue 6/2010

Login to get access

Abstract

Background

Serum cystatin C is not only a marker of renal function but also acts as an independent risk factor for cardiovascular damage, heart failure, and death. It is known that the initiation and progression of these cardiovascular events contributes to renal dysfunction and chronic inflammation. In this study, we investigated the relationship between cystatin C and proinflammatory cytokines.

Methods

Eighty-eight patients with essential hypertension participated in the study, which involved measuring proinflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and C reactive protein (CRP).

Results

Positive correlations were detected between cystatin C and estimated glomerular filtration rate (eGFR) (r = −0.503, p < 0.001), systolic blood pressure (r = −0.246, p = 0.034), and pulse pressure (r = −0.295, p = 0.010). In contrast, serum creatinine correlated only with eGFR (r = −0.755, p < 0.001) and eGFR correlated only with age (r = −0.339, p = 0.001) and not with the other clinical parameters, whereas cystatin C also correlated with log natural (ln) IL-6 (r = −0.247, p = 0.033) and ln TNF-α (r = −0.405, p < 0.001) but not with CRP (r = −0.188, p = 0.108). In contrast, plasma creatinine and eGFR did not correlate with any of these proinflammatory cytokines. Stepwise regression analysis showed that ln TNF-α, eGFR and pulse pressure were independent determinants of serum cystatin C concentration.

Conclusion

This study showed that cystatin C is a marker of inflammation as well as renal function.
Literature
1.
go back to reference Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312–8.CrossRefPubMed Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312–8.CrossRefPubMed
2.
go back to reference Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40:1921–6.PubMed Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40:1921–6.PubMed
3.
go back to reference Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268:287–94.PubMed Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268:287–94.PubMed
4.
go back to reference Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45:97–101.CrossRefPubMed Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45:97–101.CrossRefPubMed
5.
go back to reference Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, et al. Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol. 1997;48:104–8.PubMed Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, et al. Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol. 1997;48:104–8.PubMed
6.
go back to reference Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and b2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. 1985;218:499–503.CrossRefPubMed Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and b2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. 1985;218:499–503.CrossRefPubMed
9.
go back to reference Lacy F, O’Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291–303.CrossRefPubMed Lacy F, O’Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291–303.CrossRefPubMed
10.
go back to reference Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–54.CrossRefPubMed Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–54.CrossRefPubMed
11.
go back to reference Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403.PubMed Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403.PubMed
12.
go back to reference Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857–61.CrossRefPubMed Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857–61.CrossRefPubMed
13.
go back to reference O’Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med. 2005;165:2666–70.CrossRefPubMed O’Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med. 2005;165:2666–70.CrossRefPubMed
14.
go back to reference Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. data from the Heart and Soul Study. Circulation. 2007;115:173–9.CrossRefPubMed Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. data from the Heart and Soul Study. Circulation. 2007;115:173–9.CrossRefPubMed
15.
go back to reference Saenak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497–505. Saenak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497–505.
16.
go back to reference Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–60.CrossRefPubMed Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–60.CrossRefPubMed
17.
go back to reference Watanabe S, Okura T, Miyoshi K, Fukuoka T, Hiwada K, Higaki J. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895–9.CrossRefPubMed Watanabe S, Okura T, Miyoshi K, Fukuoka T, Hiwada K, Higaki J. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895–9.CrossRefPubMed
18.
go back to reference Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 2008;71:239–44.CrossRef Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 2008;71:239–44.CrossRef
19.
go back to reference Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006;28:451–61.CrossRefPubMed Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006;28:451–61.CrossRefPubMed
20.
go back to reference Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.CrossRefPubMed Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.CrossRefPubMed
21.
go back to reference Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–71.CrossRefPubMed Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–71.CrossRefPubMed
22.
go back to reference Okura T, Watanabe S, Miyoshi K, Fukuoka T, Higaki J. Intrarenal and carotid hemodynamics in patients with essential hypertension. Am J Hypertens. 2004;17:240–4.CrossRefPubMed Okura T, Watanabe S, Miyoshi K, Fukuoka T, Higaki J. Intrarenal and carotid hemodynamics in patients with essential hypertension. Am J Hypertens. 2004;17:240–4.CrossRefPubMed
23.
go back to reference Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med. 2008;148:501–8.PubMed Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med. 2008;148:501–8.PubMed
24.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
25.
go back to reference Herbelin A, Ureña P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991;39:954–60.CrossRefPubMed Herbelin A, Ureña P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991;39:954–60.CrossRefPubMed
26.
go back to reference Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis. Kidney Int. 1994;45:890–6.CrossRefPubMed Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis. Kidney Int. 1994;45:890–6.CrossRefPubMed
27.
go back to reference Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–36.CrossRefPubMed Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–36.CrossRefPubMed
28.
go back to reference Frendéus KH, Wallin H, Janciauskiene S, Abrahamson M. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int J Biochem Cell Biol. 2009;41:2262–9.CrossRefPubMed Frendéus KH, Wallin H, Janciauskiene S, Abrahamson M. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int J Biochem Cell Biol. 2009;41:2262–9.CrossRefPubMed
29.
go back to reference Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.CrossRefPubMed Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.CrossRefPubMed
30.
go back to reference Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007;22:1087–92.CrossRefPubMed Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007;22:1087–92.CrossRefPubMed
31.
go back to reference Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.CrossRefPubMed Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.CrossRefPubMed
Metadata
Title
Association between cystatin C and inflammation in patients with essential hypertension
Authors
Takafumi Okura
Masanori Jotoku
Jun Irita
Daijiro Enomoto
Tomoaki Nagao
Veena Rasika Desilva
Shiho Yamane
Zuowei Pei
Shiho Kojima
Yasuyuki Hamano
Shinichi Mashiba
Mie Kurata
Ken-ichi Miyoshi
Jitsuo Higaki
Publication date
01-12-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0334-8

Other articles of this Issue 6/2010

Clinical and Experimental Nephrology 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.